Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | Q2056 |
Short Description | Ciltacabtagene car-pos t |
Long Description | Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | |
BETOS2 code | O1D |
Action code | N |
Type of service | 1 |
Effective date | 2022-10-01 |
Date Added | 2022-10-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
57894011101 | Q2056 | Ciltacabtagene car-pos t | Carvykti | Janssen Biotech, Inc. | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | 1 | 1 | 1 | 1 |
57894011102 | Q2056 | Ciltacabtagene car-pos t | Carvykti | Janssen Biotech, Inc. | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | 1 | 1 | 1 | 1 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells |
HCPCS/CPT Billing Units | 0.01 |
Total doses ordered | |
Billing Units | 0.01 |